Sunitinib paves the way for targeted therapies in neuroendocrine tumors Eric RaymondSandrine FaivrePhilippe Ruszniewski Editorial 13 November 2009 Pages: 253 - 254
Targeting insulin-like growth factor type 1 receptor in cancer therapy Francesco AtzoriTiffany A. TrainaBruno Massidda Review 30 October 2009 Pages: 255 - 266
Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors Austin DuffyShivaani Kummar Review 10 November 2009 Pages: 267 - 273
Targeted therapies in thyroid cancer Jaume CapdevilaJose Perez-GarciaJosep Tabernero Review 11 November 2009 Pages: 275 - 285
Molecular targeted therapies in the treatment of gastroenteropancreatic neuroendocrine tumors Jaume CapdevilaRamon Salazar Review 07 November 2009 Pages: 287 - 296
Axitinib—a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor Ronan J. KellyOlivier Rixe Review 30 October 2009 Pages: 297 - 305
Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon? V. SibaudJP. DelordC. Chevreau Day-to-Day Practice 07 November 2009 Pages: 307 - 310
Implications of KRAS mutation status for the treatment of metastatic colorectal cancer Fortunato CiardielloSabine TejparDemetris Papamichael Perspectives 14 November 2009 Pages: 311 - 322